BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
木曜日, 10 01

Cullinan Therapeutics Inc

CGEMNASDAQ
Trade with Public
Trade with Public
$15.35
0.120.79%
近くで: Sep 30, 5:00 PM EST
$15.35
N/A
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Cullinan Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cullinan Therapeutics (CGEM).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy
Consensus RatingBuy# Analysts10Avg. Consensus PT$30Upside to Avg. PT+96.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 25, 2026HC Wainwright & Co.Robert BurnsPT RaiseBuy$30→$35
Sep 25, 2026BTIGJulian HarrisonMaintainedBuy$40
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.
Benzinga Newsdesk

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.
Benzinga Newsdesk

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Vandana Singh

PRO
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved